Skip to main content
Menu

Select a tool from the sidebar

Portfolio
Loading...
Sign In Get Started
Thermo Fisher Scientific Inc. (TMO)
TMO
Thermo Fisher Scientific Inc. (TMO)
662.0600 $
+5.4800 (%+0.83)
Overview
Technicals
Financial Statements
Comments
Archive

TMO: Thermo Fisher Scientific Inc. Financials

Income statement, balance sheet, cash flow and financial performance data for Thermo Fisher Scientific Inc..

Thermo Fisher Scientific Inc. Income Statement

Chart
Gross margin TTM
37.66%
Operating margin TTM
18.2%
Net profit margin TTM
15.12%
Return on investment TTM
12.61%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue44,556,000,00042,879,000,00042,857,000,00044,915,000,000
Operating income8,109,000,0007,662,000,0007,446,000,0008,525,000,000
Net income6,737,000,0006,335,000,0005,995,000,0006,950,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue44,556,000,00042,879,000,00042,857,000,00044,915,000,000
Cost of revenue27,778,000,00025,151,000,00025,663,000,00025,904,000,000
Gross profit16,778,000,00017,728,000,00017,194,000,00019,011,000,000
Research and development expenses1,397,000,0001,390,000,0001,337,000,0001,471,000,000
General and administrative expenses0000
Selling and marketing expenses0000
Selling, general and administrative expenses7,272,000,0008,676,000,0008,411,000,0009,015,000,000
Other expenses0000
Operating expenses8,669,000,00010,066,000,0009,748,000,00010,486,000,000
Cost and expenses36,447,000,00035,217,000,00035,411,000,00036,390,000,000
Net interest income-426,000,000-576,000,000-612,000,000-454,000,000
Interest income993,000,0001,078,000,000879,000,000272,000,000
Interest expense1,419,000,0001,654,000,0001,491,000,000726,000,000
Depreciation and amortization2,780,000,0003,108,000,0003,406,000,0003,381,000,000
EBITDA11,466,000,00011,800,000,00011,195,000,00011,942,000,000
EBIT8,686,000,0008,692,000,0007,789,000,0008,561,000,000
Non-operating income (excl. interest)-577,000,000-1,030,000,000-343,000,000-36,000,000
Operating income8,109,000,0007,662,000,0007,446,000,0008,525,000,000
Total other income/expenses (net)-842,000,000-667,000,000-1,207,000,000-862,000,000
Income before tax7,267,000,0006,995,000,0006,239,000,0007,663,000,000
Income tax expense547,000,000657,000,000284,000,000703,000,000
Net income from continuing operations6,720,000,0006,338,000,0005,955,000,0006,960,000,000
Net income from discontinued operations0000
Other adjustments to net income34,000,000000
Net income6,737,000,0006,335,000,0005,995,000,0006,950,000,000
Net income deductions0000
Bottom line net income6,704,000,0006,335,000,0005,995,000,0006,950,000,000
EPS18171618
Diluted EPS18171518
Weighted average shares outstanding376,000,000382,000,000386,000,000392,000,000
Weighted average diluted shares outstanding377,000,000383,000,000388,000,000394,000,000

Thermo Fisher Scientific Inc. Balance Sheet

Period endTotal assetsTotal liabilities & equity
31/12/2025110,343,000,00056,807,000,000
31/12/202497,321,000,00047,650,000,000
31/12/202398,726,000,00051,884,000,000
31/12/202297,154,000,00053,006,000,000
Long-term debt / assets MRQ
35,852,000,000%
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets110,343,000,00097,321,000,00098,726,000,00097,154,000,000
Total liabilities56,807,000,00047,650,000,00051,884,000,00053,006,000,000
Total equity53,407,000,00049,584,000,00046,735,000,00043,978,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents9,852,000,0004,019,000,0008,083,000,0008,524,000,000
Short-term investments253,000,0001,561,000,00000
Cash and short-term investments10,105,000,0005,580,000,0008,083,000,0008,524,000,000
Net receivables10,566,000,0009,626,000,0009,664,000,0009,427,000,000
Accounts receivable8,900,000,0009,626,000,0008,221,000,0008,115,000,000
Other receivables1,666,000,00001,443,000,0001,312,000,000
Inventory5,425,000,0004,978,000,0005,088,000,0005,634,000,000
Prepaid expenses0000
Other current assets2,611,000,0001,953,000,0001,760,000,0001,644,000,000
Total current assets28,707,000,00022,137,000,00024,589,000,00025,229,000,000
Property, plant and equipment (net)10,565,000,00010,795,000,00011,004,000,00010,873,000,000
Goodwill49,362,000,00045,853,000,00044,020,000,00041,196,000,000
Intangible assets15,838,000,00015,533,000,00016,670,000,00017,478,000,000
Goodwill and intangible assets65,200,000,00061,386,000,00060,690,000,00058,674,000,000
Long-term investments0560,000,00059,000,000155,000,000
Tax assets0000
Other non-current assets5,871,000,0002,443,000,0002,384,000,0002,223,000,000
Total non-current assets81,636,000,00075,184,000,00074,137,000,00071,925,000,000
Other assets0000
Total assets110,343,000,00097,321,000,00098,726,000,00097,154,000,000
Total payables3,622,000,0003,079,000,0002,872,000,0003,381,000,000
Accounts payable3,622,000,0003,079,000,0002,872,000,0003,381,000,000
Other payables0000
Accrued expenses5,324,000,0001,988,000,0001,596,000,0002,095,000,000
Short-term debt3,533,000,0002,475,000,0003,872,000,0005,851,000,000
Capital lease obligations (current)0000
Tax payables0000
Deferred revenue2,710,000,0002,852,000,0002,689,000,0002,601,000,000
Other current liabilities02,938,000,0002,983,000,0003,082,000,000
Total current liabilities15,189,000,00013,332,000,00014,012,000,00017,010,000,000
Long-term debt35,852,000,00029,061,000,00031,308,000,00028,909,000,000
Capital lease obligations (non-current)01,239,000,0001,244,000,0001,313,000,000
Deferred revenue (non-current)01,138,000,0001,499,000,0001,179,000,000
Deferred tax liabilities (non-current)1,493,000,0001,268,000,0001,922,000,0002,849,000,000
Other non-current liabilities4,273,000,0001,612,000,0001,899,000,0001,746,000,000
Total non-current liabilities41,618,000,00034,318,000,00037,872,000,00035,996,000,000
Other liabilities0000
Capital lease obligations01,239,000,0001,244,000,0001,313,000,000
Total liabilities56,807,000,00047,650,000,00051,884,000,00053,006,000,000
Treasury stock-22,309,000,000-19,226,000,000-15,133,000,000-12,017,000,000
Preferred stock0000
Common stock445,000,000444,000,000442,000,000441,000,000
Retained earnings59,156,000,00053,102,000,00047,364,000,00041,910,000,000
Additional paid-in capital18,563,000,00017,962,000,00017,286,000,00016,743,000,000
Accumulated other comprehensive income/loss-2,448,000,000-2,697,000,000-3,224,000,000-3,099,000,000
Other stockholders' equity0-1,000,00000
Total stockholders' equity53,407,000,00049,584,000,00046,735,000,00043,978,000,000
Total equity53,536,000,00049,671,000,00046,842,000,00044,148,000,000
Minority interest129,000,00087,000,000107,000,000170,000,000
Total liabilities and total equity110,343,000,00097,321,000,00098,726,000,00097,154,000,000
Total investments253,000,0002,121,000,00059,000,000155,000,000
Total debt39,385,000,00032,775,000,00036,424,000,00036,073,000,000
Net debt29,533,000,00028,766,000,00028,341,000,00027,549,000,000

Thermo Fisher Scientific Inc. Cash Flow Statement

Chart
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations7,818,000,0008,667,000,0008,406,000,0009,154,000,000
Cash from investing-4,047,000,000-5,841,000,000-5,142,000,000-2,159,000,000
Cash from financing1,801,000,000-6,792,000,000-3,622,000,000-2,810,000,000
Net change in cash5,839,000,000-4,057,000,000-440,000,0004,046,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income6,721,000,0006,338,000,0005,995,000,0006,960,000,000
Depreciation and amortization2,780,000,0003,108,000,0003,406,000,0003,381,000,000
Deferred income tax-639,000,000-1,209,000,000-1,300,000,000-995,000,000
Stock-based compensation310,000,000301,000,000278,000,000307,000,000
Change in working capital-1,766,000,000-334,000,000-537,000,000-1,049,000,000
Accounts receivable-426,000,000-171,000,000209,000,000-430,000,000
Inventory-74,000,000-27,000,000598,000,000-825,000,000
Accounts payable421,000,000212,000,000-500,000,000648,000,000
Other working capital-1,687,000,000-348,000,000-844,000,000-442,000,000
Other non-cash items412,000,000463,000,000564,000,000550,000,000
Net cash from operating activities7,818,000,0008,667,000,0008,406,000,0009,154,000,000
Investments in property, plant and equipment-1,525,000,000-1,400,000,000-1,479,000,000-2,243,000,000
Acquisitions (net)-4,037,000,000-3,132,000,000-3,660,000,000-39,000,000
Purchases of investments-383,000,000-3,396,000,0000-15,000,000
Sales/maturities of investments1,565,000,0001,770,000,00070,000,00015,000,000
Other investing activities333,000,000317,000,000-73,000,000123,000,000
Net cash from investing activities-4,047,000,000-5,841,000,000-5,142,000,000-2,159,000,000
Net debt issuance5,347,000,000-2,403,000,000-155,000,000654,000,000
Long-term net debt issuance5,347,000,000-2,403,000,000160,000,0002,818,000,000
Short-term net debt issuance00-315,000,000-2,164,000,000
Net stock issuance-3,000,000,000-4,000,000,000-3,000,000,000-3,000,000,000
Net common stock issuance-3,000,000,000-4,000,000,000-3,000,000,000-3,000,000,000
Common stock issuance0000
Common stock repurchased-3,000,000,000-4,000,000,000-3,000,000,000-3,000,000,000
Net preferred stock issuance0000
Net dividends paid-636,000,000-583,000,000-523,000,000-455,000,000
Common dividends paid-636,000,000-583,000,000-523,000,000-455,000,000
Preferred dividends paid0000
Other financing activities90,000,000194,000,00056,000,000-9,000,000
Net cash from financing activities1,801,000,000-6,792,000,000-3,622,000,000-2,810,000,000
Effect of FX changes on cash267,000,000-91,000,000-82,000,000-139,000,000
Net change in cash5,839,000,000-4,057,000,000-440,000,0004,046,000,000
Cash at end of period9,879,000,0004,040,000,0008,097,000,0008,537,000,000
Cash at beginning of period4,040,000,0008,097,000,0008,537,000,0004,491,000,000
Operating cash flow7,818,000,0008,667,000,0008,406,000,0009,154,000,000
Capital expenditure-1,525,000,000-1,400,000,000-1,479,000,000-2,243,000,000
Free cash flow6,293,000,0007,267,000,0006,927,000,0006,911,000,000
Income taxes paid01,834,000,0001,482,000,0001,234,000,000
Interest paid01,570,000,0001,385,000,000667,000,000